REVA Medical appointed Board member Ray Larkin as Chairman of its Board of Directors

– USA, CA – REVA Medical, Inc. (ASX:RVA), announced today that its Board of Directors has appointed Ray Larkin Jr., a current member of the Company’s Board of Directors, as Chairman of the Board, effective September 18, 2017. Mr. Larkin replaced Brian Dovey, who stepped down as Chairman, but will remain on the Company’s Board of Directors.

REVA’s Chief Executive Officer, Ms. Reggie Groves said, “We are looking forward to working with Ray as our new Chairman. It is an exciting time for the Company as we embark on the commercialization of Fantom. Ray has a tremendous amount of experience that will help us as we transition from an R&D organization to a fully commercial enterprise focused on growing sales and expanding our product portfolio.”

Mr. Larkin stated, “I am excited to work with the REVA management team as we transform the Company and commercialize Fantom in Europe. We are well positioned to drive the Company towards future growth.”

Ms. Groves continued, “We also offer our thanks to Brian Dovey for his dedication and contributions to REVA as Chairman of the Board. We appreciate his guidance and leadership and we are very pleased that he will continue to serve on the Company’s Board.”

About REVA

REVA is a medical device company located in San Diego, California, USA, that has developed and commercialized a proprietary bioresorbable scaffold, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s Fantom scaffold, which received European CE Marking on April 3, 2017, is designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>